
|Videos|July 21, 2022
How Ruxolitinib Will Change the Future of Vitiligo Treatment
Author(s)Kaitlyn Bader, Associate Editor
Pearl Grimes, MD, FAAD, and director of the Grimes Center of Medical and Aesthetic Dermatology and the Vitiligo & Pigmentation Institute of Southern California in Los Angeles, explains why the FDA approval of ruxolitinib cream 1.5% is monumental in the treatment of vitiligo.
Advertisement
Newsletter
Like what you’re reading? Subscribe to Dermatology Times for weekly updates on therapies, innovations, and real-world practice tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Dermatology Times
1
When Hives Do Not Quit: A Practical Update on Chronic Spontaneous Urticaria
2
KT-621 Produces 98% STAT6 Degradation in AD Patients
3
Delgocitinib Offers Targeted Relief for the Painful Burden of Chronic Hand Eczema
4
Site-Specific MED Variability Guides 308-nm Excimer Laser Dosing
5



















